Download MendeleyDiscovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1 beta.
Hommel, U., Hurth, K., Rondeau, J.M., Vulpetti, A., Ostermeier, D., Boettcher, A., Brady, J.P., Hediger, M., Lehmann, S., Koch, E., Blechschmidt, A., Yamamoto, R., Tundo Dottorello, V., Haenni-Holzinger, S., Kaiser, C., Lehr, P., Lingel, A., Mureddu, L., Schleberger, C., Blank, J., Ramage, P., Freuler, F., Eder, J., Bornancin, F.(2023) Nat Commun 14: 5497-5497
- PubMed: 37679328
- DOI: https://doi.org/10.1038/s41467-023-41190-0
- Primary Citation of Related Structures:
8C3U - PubMed Abstract:
Human interleukin-1β (hIL-1β) is a pro-inflammatory cytokine involved in many diseases. While hIL-1β directed antibodies have shown clinical benefit, an orally available low-molecular weight antagonist is still elusive, limiting the applications of hIL-1β-directed therapies. Here we describe the discovery of a low-molecular weight hIL-1β antagonist that blocks the interaction with the IL-1R1 receptor. Starting from a low affinity fragment-based screening hit 1, structure-based optimization resulted in a compound (S)-2 that binds and antagonizes hIL-1β with single-digit micromolar activity in biophysical, biochemical, and cellular assays. X-ray analysis reveals an allosteric mode of action that involves a hitherto unknown binding site in hIL-1β encompassing two loops involved in hIL-1R1/hIL-1β interactions. We show that residues of this binding site are part of a conformationally excited state of the mature cytokine. The compound antagonizes hIL-1β function in cells, including primary human fibroblasts, demonstrating the relevance of this discovery for future development of hIL-1β directed therapeutics.
Organizational Affiliation:
Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002, Basel, Switzerland. uli.hommel@icloud.com.
